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Abstract
Studying the cellular function of microRNAs requires genetic strategies to generate their loss-of-function. Recently, 
a novel approach of targeted genomic deletion was proposed, which is based on induction of site-specific DNA cuts 
with Cas9/gRNA ribonucleoprotein complexes, combined with homologous recombination-dependent insertion of 
cassettes that contain sequences for Cre-lox or FLP-FRT systems. Here, we provide a technical report describing 
application of this CRISPR/Cas9-directed homologous recombination procedure to the generation of human tumor 
cells in which conditional knockout of an X-linked cluster of microRNAs (miR-105/miR-767) can be induced. We 
describe the successive steps of genetic engineering and cell clone selection that allowed us to generate cells with the 
expected genome editing. 
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Introduction
MicroRNAs (miRNAs) are small noncoding RNAs that exert 
important cellular functions by repressing post-transcriptional gene 
expression through binding to target mRNAs [1]. More than 60% 
of all human genes are predicted to be regulated by a total of over 
2.000 mature miRNAs. Some miRNAs are expressed in virtually all 
cell types, whereas others are highly tissue-specific with a distinct 
function depending on cell type or organ. miRNAs play key roles in 
most biological processes, including cell division and death, cellular 
metabolism, intracellular signaling, immunity and cell movement. Not 
surprisingly, disregulation of miRNA expression has been functionally 
linked to various pathological and occasionally malignant outcomes [2]. 
Specific miRNA expression patterns, which have been associated with 
particular diseases, hold great prognostic value. In cancer, oncogenic 
miRNAs as well as tumor suppressor miRNAs have been identified, and 
therapeutic strategies directed against such cancer-related miRNA are 
being considered [3,4]. 
The physiological roles of most miRNAs still need to be deciphered. 
Therefore, tools allowing manipulation of miRNA activity are required. 
Gain-of-function by over-expression of the miRNA is relatively easy, 
and can be achieved by transfection of synthetic microRNAs or by 
enforcing expression of primary miRNA transcripts [5,6]. Loss-
of-function analyses are less obvious. miRNA inhibitors based on 
synthetic antisense molecules or miRNA sponges, which act by binding 
and sequestering miRNAs away from their natural targets, are available 
[7]. However, such inhibitors have some disadvantages, including 
incomplete masking of miRNA function, and uncontrolled off-target 
effects.
Genome engineering is a powerful tool for dissecting biological 
mechanisms. The Clustered, Regularly Interspaced, Short Palindromic 
Repeats (CRISPR) / CRISPR-associated protein 9 (Cas9) system 
provides a rapid and efficient technology for targeted genome editing. 
In association with a specifically designed guide RNA (gRNA), 
Cas9 can achieve site-specific DNA recognition and cleavage [8]. A 
constraint in this genome editing process is the compulsory presence of 
a Protospacer Adjacent Motif (PAM) sequence near the Cas9 cleavage 
site. In most cases, the site-specific DNA double-strand breaks (DSB) 
induced by Cas9 triggers a non-homologous end-joining (NHEJ) 
process of DNA repair, leading to small insertions or deletion in the 
nucleotidic sequence. This procedure is therefore exploited to generate 
loss-of-function of protein coding genes, via alteration of the open 
reading frame. Short miRNAs are less amenable to this editing process, 
as many of them do not carry the required PAM motif within their 
sequence. 
An alternative use of the CRISPR/Cas9 technology, which would 
be better adapted to manipulate miRNAs, has been proposed. In this 
setting, Cas9 cleavages are used to direct homologous recombination-
dependent insertion of cassettes that contain LoxP or FRT sequences 
up- and downstream of the miRNA locus, thereby allowing subsequent 
deletion of the embedded sequence upon expression of Cre or FLP 
recombinases. This procedure requires that template DNA sequences 
with homologous arms are provided to the cells, in order to stimulate 
homology-directed repair (HDR) of the Cas9-iduced DSB [9]. 
Examples where this technology was used to delete a miRNA locus 
remain however scarce [10,11]. Here, we report successful application 
of this procedure to the generation of human tumor cells in which a 
miRNA locus can be conditionally deleted. The locus targeted in our 
study corresponds to an X-linked cluster of two miRNAs (miR-105 and 
miR-767), which were recently shown to display aberrant activation in 
wide variety of tumors, and to exert oncogenic potential [12,13].
Materials and Methods
Cell culture and transfection
HT1080, LB2201-MEL, Mi13443, SK-MES1, GLCP1 cell lines 
were cultured in Iscove’s modified Dulbecco’s medium (IMDM, Life 
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Technologies) and HEK293 cell line in 4,5 g/l D-glucose Dulbecco’s 
modified Eagle’s medium (DMEM, Life Technologies). All media were 
supplemented with 10% fetal bovine serum (FBS, Life Technologies) 
and contained 1x non-essential amino acids (Life Technologies) and 1x 
Penicillin/Streptomycin (Life Technologies). 
DNA transfection was performed in a T75 flasks, with 2 to 6 
millions cells, using Lipofectamine 2000® Reagent (Invitrogen). Five 
hours after transfection, the medium was replaced. The amount of 
transfected DNA was 5 µg of Cas9/sgRNAs vectors and 5 µg of donor 
pEZ-Frt-lox-5’ or pEZ-Frt-lox-3’ vectors. Prior to transfection, pEZ-
Frt-lox-5’ vector was linearized 5’ to the left homology arm by digestion 
with the EcoRV restriction enzyme, and the pEZ-Frt-lox-3’ vector 
was digested by EcoRV and XhoI restriction enzymes. Transfectants 
were selected for 15 days in medium containing 0.8 to 2 mg/ml of 
geneticin, depending on the type of cells. Two weeks after transfection, 
integration of the donor DNA was tested by PCR amplification with 
primers encompassing the recombinant fragment on genomic DNA. 
Cell populations showing effective recombination were cloned by 
limiting dilutions. 
For Cre or FLP recombination, cells were transiently transfected 
using Lipofectamine 2000® Reagent (Invitrogen) in 6-well plates with 
2 µg of CMV-Cre or pCAGGS-FLPe vectors, and cloned by limiting 
dilution 72h after transfection.
Plasmid design and construction
The pX330-U6-Chimeric_BB-CHb-hSpCas9 vector (available at 
Addgene, and kindly provided by P. Coulie) was digested using Fast-
Digest BbsI (Thermo Scientific) and double-stranded oligonucle-
otides corresponding to different spacer sequences were ligated with 
T4 DNA ligase (Thermo Scientific) generating different sgRNAs. 
Double-stranded oligonucleotides for spacer sequences were ob-
tained by annealing pairs of complementary oligos (Eurogentec) com-
posed of the spacer sequence flanked by adapter sequences (Forward: 
5’-CAACG…-3’; Complement: 5’-AAAC…C-3’). Design of spacer se-
quences was based on CRISPR Design Tool of ZhangLab (http://crispr.
mit.edu)  generating: sgRNA1 5’ -TTTGTGTAATGGGATCGTTTGG; 
sgRNA2, 5’-GGGGATAGATATGGTATCCCAGG; sgRNA3 5’-CAAT-
CATTGTCTACTTGTACTGG; sgRNA4 5’-CTGCAACATGAGCT-
GATACCAGG; sgRNA5 5’- TGGTAGACTGAGCACGCGTAAGG; 
sgRNA6 5’- GGTCGTCTGATGTTATACCTTGG; sgRNA7 5’- AG-
GAATTCTTTCCCGTATTGTGG; sgRNA8 5’- TACGCGTGCT-
CAGTCTACCATGG.
Donor vector constructions were performed on the basis of the 
pEZ-Frt-lox-DT vector (Addgene). Left (LHA) and right (RHA) ho-
mology arms (~300 to ~800 pb) were amplified by PrimeSTAR HS 
DNA Polymerase (Takara) from HT1080 genomic DNA using comple-
mentary primers flanked by restriction site sequence at the 5’ end. For 
the pEZ-Frt-lox-5’ vector, primers to amplify LHA were flanked with 
EcoRV and NotI sites (sense: 5-attaGATATCtaggcatgtgttcatccgagga; 
reverse: 5’-attaGCGGCCGCgatcccattacacaaactaacagc), and primers to 
amplify RHA were flanked with HindIII and XhoI sequences (sense: 
5’-attaAAGCTTgtttggatttatatcatgcccaaac; reverse: 5’-attaCTCGAG-
gataccaggttatagggagtaga). For the pEZ-Frt-lox-3’ vector, primers to 
amplify LHA were flanked with EcoRV and NotI sites (sense: 5’-atta-
GATATCgtgtatgtgcacaatgctcact; reverse: 5’-attaGCGGCCGCccatg-
gagaatgagccaatact), and primers to amplify RHA were flanked with SalI 
and XhoI sequences (sense: 5’- attaGTCGACtagactgagcacgcgtaaggaa; 
reverse: 5’-attaCTCGAGccatagactggtacttaccgaga). PCR products were 
digested with the appropriate restriction enzymes, and purified (QIA-
quick Gel Extraction Kit, Qiagen), prior to ligation with T4 DNA ligase 
(Thermo Scientific) into the pre-digested vector. pEZ-Frt-lox-DT vec-
tor was pre-digested with EcoRV-NotI for the insertion of both LHA, 
and with HindIII-XhoI or SalI-XhoI for introduction of RHA to pEZ-
Frt-lox-5’ or pEZ-Frt-lox-3’ vectors, respectively. All PCR products and 
final vectors were verified by DNA sequencing.
DNA preparation and PCR
Two weeks after cloning, HT1080 clones were removed from 96-well 
plates with 2 mM EDTA/PBS. Half of the cells were reseeded in 24-well 
plate and the other half was used for DNA extraction. Cells were placed 
in a lysis buffer composed by 10mM Tris pH8, 10 mM EDTA, 1% SDS 
and 0.1 mg/ml of proteinase K (New England BioLabs). After overnight 
incubation at 45°C, DNA was extracted by organic extraction with 
phenol:chloroform and 1 µg of salmon sperm DNA was added to help 
isopropanol precipitation. PCR S1-4 (Forward: 5’-gtcactggctcctgcagaat; 
reverse: 5’-gaagcagatggcaatgttgcaa), PCR S5-8 (Forward: 5’-gagaat-
gtctggttgtgtacctt; Reverse: 5’-caggcaaacacgatactgtcaa), PCR A (For-
ward: 5’-cactgtcatcttatccttaactga; Reverse: 5’-ctcgaccatatgggagagct), 
PCR B (Forward: 5’-gacgagttcttctgagggga; Reverse: 5’-atttgaccacgatgca-
cacaca), PCR C (Forward: 5’-ggctcctgcagaatgggtat; Reverse: 5’-acaccta-
caggacataggctat), PCR D (Forward: 5’-atatgaggaagcatggcaccat; Reverse: 
5’-ctcgaccatatgggagagct), PCR E (Forward: 5’-gacgagttcttctgagggga; 
Reverse: 5’-gataactatggtgatgcacataca), PCR F (Forward: 5’-atatgag-
gaagcatggcaccat; Reverse: 5’-gataactatggtgatgcacataca), PCR G (For-
ward: 5’-ggctcctgcagaatgggtat; Reverse: 5’-tgctacctctaatggatatggtaa), 
PCR 105 (Forward: attctcgagccctttagctatggtcttctgct; Reverse: gatacgc-
gttgatggtgccatgcttcctca) and PCR 767 (Forward: 5’-attctcgagtttaacagt-
caaatattagtgttagttgct; Reverse: 5’-gatacgcgtcagccatcacatcataggca) were 
performed using Dream Taq polymerase (Thermo Scientific) on 1/3 of 
the total extracted DNA. 
DNA extracted from total cell populations was performed similarly, 
but without addition of salmon sperm DNA. DNA concentrations were 
quantified with a NanoDrop ND-1000 (NanoDrop Technologies), and 
PCR were performed on 100 ng of genomic DNA per reaction.
RNA preparation and RT-qPCR evaluation of miRNA 
expression levels
We isolated total RNA using TriPure Isolation Reagent (Roche) 
according to the manufacturer’s protocol, and used 100ng of this RNA 
for reverse transcription with the miRCURY LNATM Universal RT 
microRNA PCR (Exiqon). The resultant cDNA was diluted 20 times, 
and a 2.5 µl aliquot was used in a SYBRGREEN qPCR with LNA 
specific primers for miR-105 and miR-767 (Exiqon). RNU44 was used 
as internal control.
Flow cytometry cell sorting
HT1080 #72.2.25.9 clone was transiently transfected by pTM945-
Cre-IRES-mCherry vector or control vector pTM945-mCherry, coding 
both for mCherry fluorescent protein. Two days later, cells were sorted 
by fluorescence-activated cell sorting (FACS, FACSAriaTM III, BD 
Biosciences) based on mCherry signal. The sorted populations were 
harvested for RT-qPCR analysis 6 to 34 days after reseeding.
Detection of gRNA efficiency
HT1080 cells were transfected with pX330-U6-Chimeric_BB-CBh-
hSpCas9 vector carrying 8 different sgRNAs, named Cas9/sgRNA1-8. 
Three days after transfection, DNA extracted from those cells was treated 
with RNAse A and submitted to SURVEYOR® Mutation Detection Kit, 
according to the manufacturer’s recommendations (Transgenomic). In 
brief, the genomic region flanking the CRISPR/Cas9 target site was first 
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amplified by PCR using PrimeSTAR HS DNA polymerase (Takara). 
After migration through agarose gel, PCR products were purified 
using QIAquick Gel Extraction Kit (Qiagen). 2 µg of the purified PCR 
products were mixed with 10x Surveyor Buffer (100 mM Tris, 500 mM 
KCl, 15mM MgCl2) and water to a final volume of 20 µl, and subjected 
to a re-annealing process to enable heteroduplex formation: 95°C for 
10min, 95°C to 85°C ramping at − 2°C/s, 85°C to 25°C at − 0.25°C/s, 
and 25°C hold for 1 minute. After re-annealing, PCR products were 
treated with 1 µl of SURVEYOR nuclease and SURVEYOR enhancer 
S (Transgenomics) during 1 hour at 42°C. DNA samples were run in a 
2% agarose gel, in TAE 1x buffer supplemented with ethidium bromide. 
Quantification was performed by calculating relative band intensities 
using ImageJ software. 
Results and Discussion
General strategy for the generation of cells with conditional 
knockout of MIR105/767
The general strategy to obtain cells where the X-linked MIR105/767 
locus can be conditionally deleted is described in Figure 1 and each 
step is described in details below. In brief, the procedure involved 
successive steps of CRISPR/cas9-directed homologous recombination 
to permit integration of neomycin-loxP/FRT cassettes 3’ and 5’ to the 
MIR105/767 genomic locus, as well as exposure of cells to Cre and FLP 
(Flippase) recombinases to leave only single loxP sites on both sides. At 
each step of the procedure, a cell clone with the appropriate integration/
recombination was selected, and used for the subsequent step. 
Selection of efficient single guide RNAs (sgRNAs)
Targeting of the Cas9 nuclease to a specific site on the genome 
is commonly achieved through its association with a chimeric RNA 
construct, termed single guide RNA (sgRNA). The sgRNA includes 
the tracrRNA sequence, which allows association of the RNA molecule 
with the Cas9 enzyme, and the spacer sequence, which binds the 
genomic target by nucleotide complementarity. Not all sgRNAs are 
equally efficient. The first step to achieve our construction was therefore 
to test different sgRNAs, and to select those that stimulate site-specific 
cleavage by Cas9 with the highest efficiency (Figure 2). Using a spacer 
RNA design algorithm (http://crispr.mit.edu), we designed four 
sgRNAs for each side of the MIR105/767 locus. The corresponding 
sequences were inserted in the pX330-U6-Chimeric_BB-CBh-hSpCas9 
vector, which also carries a human codon-optimized Cas9 coding 
sequence. These different Cas9/sgRNA vectors were then transfected 
into HT1080 cells, generating DSBs at precise sgRNA targeted sites. The 
error-prone NHEJ process results in the formation of mutation or small 
insertions or deletion. Genomic DNA was collected from transfectants 
after three days. DNA cleavage efficiency was evaluated by mutation 
detection assay using the Surveyor® Mutation Detection kit. Thus, DNA 
 
The MIR105/767 locus comprises two pre-microRNA sequences (MIR105-1 and MIR105-2) for miR-105 and one (MIR767)for miR-767, represented by blue 
boxes. Refer to the text for detailed explanation on the targeting vectors, and the successive steps of cell transfection and clone selection.
Figure 1: Schematic draw depicting the strategy used for generation of a cell line with a “floxed” MIR105/767 locus.
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fragments carrying the expected cleavage site were amplified by PCR. 
Amplicons were denatured by heat, and then allowed the re-anneal 
slowly. They were then exposed to the Surveyor nuclease, which cuts 
heteroduplexes but not homoduplexes of DNA. Nuclease-treated DNA 
fragments were electrophoresed in an agarose gel, and the cleavage 
efficiency was evaluated by calculating the ratio between the cleaved 
and uncleaved band (percentage of indel). Using this method, we 
identified the sgRNAs that directed the most efficient Cas9-mediated 
cleavage either 5’ (sgRNA1, 9.3% indel) or 3’ (sgRNA8, 12.9% indel) to 
the MIR105/767 locus (Figure 2).
CRISPR/Cas9 mediated integration of a Neo-2loxP/2FRT 
cassette 5’ to the MIR105/767 locus
In order to direct homologous recombination towards the sgRNA1-
induced Cas9 cleavage site, a vector (pEZ-FRT-lox-5’) was constructed 
in which left and right homology arms were inserted on each side of a 
neomycin resistance cassette (Neo) flanked by two loxP and FRT sites 
(Neo-2loxP/2FRT; Figure 3). The left homology arm (LHA5’, 306bp) 
and the right homology arm (RHA5’, 692bp) corresponded to genomic 
sequences located upstream and downstream the Cas9/sgRNA1 cutting 
site, respectively.
We transfected Cas9/sgRNA1 and pEZ-FRT-lox-5’ vectors in 
six different human cell lines: embryonic kidney cells (HEK293), 
two melanoma cell lines (Mi13443 and LB2201-MEL), two lung 
carcinoma cell lines (GLCP1 and SKMES1), and a fibrosarcoma cell line 
(HT1080). We selected cells of male origin, as these contain only one X 
chromosome. Following transfection, cells were selected for two weeks 
in neomycin-containing medium, and part of the resistant populations 
was harvested for DNA extraction. Integration of the Neo-2loxP/2FRT 
cassette was assessed by PCR amplification with one primer matching 
a genomic sequence upstream of the LHA5’ and another primer 
corresponding to a sequence within the cassette. Of the six transfected 
cell lines, only three (HT1080, GLCP1 and SK-MES1) showed evidence 
of integration of the Neo-2loxP/2FRT cassette (Figure 3).
We decided to derive clones from the transfected HT1080 cell 
population, in order to isolate clones harboring the appropriate 
integration event. Out of 113 clones, 4 showed integration of the 
Neo-2loxP/2FRT, as evidenced by positive signals following PCR 
amplification with appropriate primers (Figure 4). Following 
verification of PCR products by sequencing, only clones #72, #76 
and #83 showed perfect recombination. The remaining clone (#29) 
showed deletions in the intersection between homology arms and the 
cassette sequence. Overall, we observed a 2.5% (3/113) efficiency of 
homologous recombination directed by CRISPR/Cas9 towards the 5’ 
side of the MIR105/767 locus in HT1080 cells. Clone HT1080#72 was 
selected for the subsequent steps.
Cre recombinase-mediated removal of the 5’ cassette
In order to obtain cells where the Neo-2loxP/2FRT cassette was 
removed and only one loxP sequence remained 5’ to the MIR105/767 
locus, HT1080#72 cells were transiently transfected with a vectors 
encoding Cre recombinase (CMV-Cre). Sub-clones were isolated, and 
screened for effective loxP recombination by PCR amplification with 
primers matching sequences in LHA5’ and RHA5’ homology arms 
(Figure 5). Out of five tested clones, two clones (#72.2 and #72.3) 
showed effective recombination. We chose clone HT1080 #72.2 for 
the subsequent steps aiming at introducing a second loxP site 3’ to the 
MIR105/767 locus.
CRISPR/Cas9-directed integration of a Neo-1LoxP/2FRT 
cassette 3’ to the MIR105/767 locus
In HT1080#72.2 cells, we next performed directed integration 
of a Neo-1loxP/2FRT cassette towards the sgRNA8-induced Cas9 
cleavage site, located on the 3’ side of the MIR105/767 locus. To this 
end, we constructed a vector (pEZ-FRT-lox-3’) in which left and right 
homology arms were inserted on each side of the Neo-1loxP/2FRT 
 
On the top panel, the schematic draw depicts localisation of each sgRNA on the MIR105/767 locus, as well as the position of primers used for PCR 
amplification prior to the Surveyor nuclease treatment. Sizes of initial (uncleaved) PCR products are also given. Transfections with each of the Cas9/sgRNA 
vectors (sgRNA1 to -8) were performed in HT1080 cells, and DNA was extracted from transfectants 3 days later. DNA samples were submitted to PCR 
amplification with indicated primers, and then exposed to Surveyor nuclease. Resulting DNA products were analyzed by gel electrophoresis. Presence of 
DNA fragments with a size lower than the original PCR product indicates efficient sgRNA-directed cleavage. The ratio between the intensity of the lower 
band and that of the starting PCR band provides a measurement of cleavage efficiency (% indel). 
Figure 2: Surveyor assay comparing the cleavage efficiency induced by eight different sgRNAs at corresponding DNA regions.
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cassette (Figure 6). The left homology arm (LHA3’, 774bp) and the right 
homology arm (RHA3’, 692bp) corresponded to genomic sequences 
located upstream and downstream of the Cas9/sgRNA8 cutting site, 
respectively. Restriction sites used for insertion of the RHA3’ into the 
vector were chosen in order to delete the neighboring loxP site.
HT1080#72.2 cells were transfected with Cas9/sgRNA8 pEZ-
FRT-lox-3’ vectors, and following neomycin selection, resistant clones 
were derived. These clones were screened for integration of the Neo-
1loxP/2FRT cassette by PCR amplification on genomic DNA, using 
primer pairs matching either sequences within the cassette or genomic 
sequences outside of the homology regions (Figure 6). PCR signals of 
the expected size were detected in 4 out 33 tested clones, indicating that 
Cas9/sgRNA8-directed homologous recombination in HT1080#72.2 
cells was obtained with an efficiency of 12,1%. Clone HT1080#72.2.25 
was selected for the subsequent steps.
Flippase mediated deletion of the 3’ cassette
 
Following transfection, indicated cell lines were submitted to 2 weeks neomycin selection, and their genomic DNA was harvested for PCR analyses. The 
upper panel depicts the annealing sites of the PCR primers used to test integration of the Neo-2loxP/2FRT cassette (PCR A). One primer is located in 
the genomic region outside of the left homology arm (LHA5’) and the other primer is located in the inserted sequence. Gel electrophoresis shows PCR 
amplification products obtained with primers for PCR A, and for the PCBD2, a gene located on chromosome 5 used as positive control. 
Figure 3: PCR screening for insertion of Neo-2loxP/2FRT cassette in six cell lines transfected with pX330-sgRNA1 and pEZ-FRT-lox-5’ vectors.
 
Following transfection with pX330-sgRNA1 and pEZ-FRT-lox-5’ vectors, HT1080 cells were selected in neomycin, and 140 cell clones were derived. Their 
DNA was submitted to PCR analyses. The picture above depicts the annealing sites of the PCR primers used for screening clones with effective homologous 
integration of the Neo-2loxP/2FRT cassette. PCR A (600bp) and PCR B (956bp) have both one primer located in genomic DNA outside the homology arms, 
and another primer located in the donor vector sequence. Recombinant clones are expected to produce a signal with both PCRs. PCR amplification of 
PCBD2 served as control. According to PCBD2 amplification, only 113 of these were analyzable. Control samples included the total population of HT1080 
cells transfected with pX330-sgRNA1/pEZ-FRT-lox-5’ (HT1080 sgRNA1), untransfected HT1080 cells, salmon sperm DNA (DSS), and water. 
Figure 4: PCR screening for Neo-2loxP/2FRT cassette insertion in HT1080 cell clones.
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The schematic draw depicts the annealing sites of the PCR C primers used to detect “floxing” of the 5’ cassette. The PCR product is expected at a size of 
408bp in case of appropriate loxP recombination (1888bp in non-recombinant cells). PCR in naïve cells is expected to yield a 355bp product. Five clones 
isolated from the CMV-Cre-transfected HT1080#72 cell population were tested. Control samples included untransfected HT1080 cells, salmon sperm DNA 
(DSS), and water.
Figure 5: PCR screening for Cre-induced loxP recombination at the 5’ cassette.
 
HT1080#72.2 cells, which had been transfected with pX330-sgRNA8 and pEZ-FRT-lox-3’ vectors, were selected in neomycin and cloned. DNA from 40 
clones was tested for insertion of the Neo-1loxP/2FRT cassette insertion 3’ to the MIR105/767 by PCR. The upper panel indicates the position of the primers 
and expected product size of the two PCR (D and E). PCR results for the PCBD2 control sequence shows that only 33/44 clones were analyzable. Control 
samples included untransfected HT1080 cells, and water.
Figure 6: PCR screening for Neo-1loxP/2FRT cassette insertion 3’ to the MIR105/767 locus in HT1080 cell clones.
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We next aimed to delete the cassette integrated 3’ to the 
MIR105/767 locus, but without removing the single loxP site. To this 
end, HT1080#72.2.25 cells were transiently transfected with a vector 
encoding Flippase, which induces recombination between FRT sites. 
Following transfection, cellular clones were isolated, and screened 
for effective FRT recombination by PCR amplification with primers 
matching sequences in LHA3’ and RHA3’ homology arms (Figure 
7). Out of 21 tested clones, 8 clones (38%) showed effective FRT 
recombination. Among these, clone HT1080 #72.2.25.9, in which the 
MIR105/767 locus is now surrounded by two loxP sites, was chosen for 
subsequent analyses.
Cre recombinase-mediated knockout of the MIR105/767 
locus
Since HT1080#72.2.25.9 cells contain loxP sequences on both 
sides of the MIR105/767 locus, their exposure to Cre recombinase is 
expected to induce deletion of the corresponding genomic region. To 
test this, HT1080#72.2.25.9 cells were transiently transfected with the 
CMV-Cre vector. Previous experiments established a 40% efficiency of 
transfection in HT1080 cells, implying that only part of the transfected 
HT1080#72.2.25.9 will effectively express Cre recombinase. We 
therefore decided to verify successful deletion of the MIR105/767 locus 
in clones isolated from the CMV-Cre transfected HT1080#72.2.25.9 
cell population. Following derivation of the clones, their DNA was 
extracted and submitted to PCR screening with three different pairs 
of primers allowing unambiguous determination of the presence or 
absence of the MIR105/767 locus (Figure 8). Among 24 tested clones, 7 
  
Clones were derived from HT1080#72.2.25 that had been transiently transfected with a Flippase-encoding vector. DNA was extracted from 21 clones, 
and analyzed by PCR to detect FRT recombination. The schematic draw depicts the annealing sites of the PCR primers used for the screening (PCR F), 
and the expected PCR product size in case of effective FRT recombination. Amplification of PCBD2 served as positive control. Control samples included 
untransfected HT1080 cells, and water.
Figure 7: PCR screening for Flippase-induced FRT recombination at the 3’ cassette.
 
HT1080#72.2.25.9 were transiently transfected with either CMV-Cre or pTM945-Cre-IRES-mCherry. CMV-Cre transfected cells were cloned, whereas 
pTM945-Cre-IRES-mCherry transfectants were sorted by FACS to isolate mCherry-expressing cells (Pop FACS Cre). A control population of cells was 
obtained after sorting cells that had been transfected with pTM945-mCherry (Pop FACS Ctrl). PCR screening was applied to cell clones (n=24) or sorted 
populations to detect deletion of the MIR105/767 locus. Three PCR amplifications were performed (PCR 767, PCR 105, PCR G). The upper panel indicates 
the position of PCR primers, and expected sizes of PCR products (following deletion for PCR G). Control samples included untransfected HT1080 cells, and water.
Figure 8: PCR analysis of Cre-induced deletion of the MIR105/767 locus.
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clones (29%) showed effective deletion of the MIR105/767 locus (Figure 8).
We next tried to facilitate the knockout procedure by avoiding the 
process of cellular cloning that followed CMV-Cre transfection. To 
this end, we replaced CMV-Cre with the pTM945-Cre-IRES-mCherry 
vector, which expresses both Cre recombinase and the mCherry 
fluorescent protein. Thus, HT1080#72.2.25.9 cells were transfected with 
pTM945-Cre-IRES-mCherry, and two days later cells with the highest 
level of fluorescence were selected by fluorescence-activated cell sorting 
(FACS) and reseeded. A control group, transfected with a similar vector 
lacking Cre recombinase (pTM945-mCherry), was treated in parallel. 
Genomic DNA was extracted from FACS sorted cells, and submitted to 
PCR screening with the above-mentioned primer pairs (Figure 8). The 
results showed efficient enrichment of cells with MIR105/767 deletion, 
although a small proportion of non-recombined cells remained (Figure 
8). We also analyzed the expression of miR-105 and miR-767 by RT-
qPCR in FACS-sorted cells. The results confirmed marked loss of 
expression of these two miRNAs in Cre-exposed cells, as only 5,6% and 
6% residual expression level was observed for miR-105 and miR-767, 
respectively (Figure 9).
Altogether, we described a genetic engineering strategy based on 
CRISPR/Cas9-directed homologous recombination, which allowed us 
to create a human tumor cell line in which the MIR105/767 locus can be 
conditionally deleted. Our data therefore confirm the feasibility of this 
strategy, and provide several guidelines concerning the experimental 
procedures. CRISPR/Cas9-directed homologous recombination was 
found to occur with an expected efficiency (2.5% and 12.1% efficiency 
for the 5’ and 3’ position, respectively). One of the pitfalls of the CRISPR/
Cas9 technology is the presence of many off-target mutations induced 
by Cas9, which renders comparisons between genetically modified 
cells uncertain. This is however not a problem in our cellular model, as 
comparisons will be made within the final clone (HT1080#72.2.25.9), 
between two cell groups that differ only for the presence or absence of 
the MIR105/767 locus. 
Acknowledgments
This work was supported by grants from the D.G. Higher Education and 
Scientific Research of the French Community of Belgium (Action de Recherches 
Concertées) and from the Fonds special de recherche (FSR) of the Université 
catholique de Louvain, Belgium. A.V.T. is recipient of a Télévie grant from the FRS-
FNRS, Belgium [#7.4581.13]. A.L. is supported by the de Duve Institute, Brussels, 
Belgium.
References
1. Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 
136: 215-233.
2. Esteller M (2011) Non-coding RNAs in human disease. Nat Rev Genet 12: 861-
874.
3. Croce CM (2009) Causes and consequences of microRNA dysregulation in 
cancer. Nat Rev Genet 10: 704-714.
4. Hayes J, Peruzzi PP, Lawler S (2014) MicroRNAs in cancer: biomarkers, 
functions and therapy. Trends Mol Med 20: 460-469.
5. Chen CZ, Li L, Lodish HF, Bartel DP (2004) MicroRNAs modulate hematopoietic 
lineage differentiation. Science 303: 83-86.
6. Wang Z (2011) The guideline of the design and validation of MiRNA mimics. 
Methods Mol Biol 676: 211-223.
7. Brown BD, Naldini L (2009) Exploiting and antagonizing microRNA regulation 
for therapeutic and experimental applications. Nat Rev Genet 10: 578-585.
8. Mali P, Yang L, Esvelt KM, Aach J, Guell M, et al. (2013) RNA-guided human 
genome engineering via Cas9. Science 339: 823-826.
9. Cong L, Ran FA, Cox D, Lin S, Barretto R, et al. (2013) Multiplex genome 
engineering using CRISPR/Cas systems. Science 339: 819-823.
10. Ho TT, Zhou N, Huang J, Koirala P, Xu M, et al. (2015) Targeting non-coding 
RNAs with the CRISPR/Cas9 system in human cell lines. Nucleic Acids Res 
43: e17.
11. Xiao A, Wang Z, Hu Y, Wu Y, Luo Z, et al. (2013) Chromosomal deletions and 
inversions mediated by TALENs and CRISPR/Cas in zebrafish. Nucleic Acids 
Res 41: e141.
12. Loriot A, Van Tongelen A, Blanco J, Klaessens S, Cannuyer J, et al. (2014) 
A novel cancer-germline transcript carrying pro-metastatic miR-105 and TET-
targeting miR-767 induced by DNA hypomethylation in tumors. Epigenetics 9: 
1163-1171.
13. Zhou W, Fong MY, Min Y, Somlo G, Liu L, et al. (2014) Cancer-secreted miR-
105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell 
25: 501-515.
RNA was extracted from Cherry-expressing (FACS-sorted) HT1080#72.2.25.9 
cells that had been previously transfected with either pTM945-Cre-IRES-
mCherry (Cre-mCherry) or pTM945-mCherry (Ctrl). RT-qPCR analyses were 
performed at 6 different time points (days 6 to 34) post-transfection. Expression 
levels are expressed relative to the level in Ctrl cells. 2 way ANOVA was used 
for statistical analysis (***, p<0,0001).
Figure 9: RT-qPCR expression analysis of miR-105 and miR-767 in FACS-
sorted Cre-induced HT1080#72.2.25.9 cells.
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